Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-656032a84c2935003bb3f7376e124521"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-656032a84c2935003bb3f7376e124521"/>
<resource>
<Composition>
<id value="composition-en-656032a84c2935003bb3f7376e124521"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-656032a84c2935003bb3f7376e124521"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-656032a84c2935003bb3f7376e124521</b></p><a name="composition-en-656032a84c2935003bb3f7376e124521"> </a><a name="hccomposition-en-656032a84c2935003bb3f7376e124521"> </a><a name="composition-en-656032a84c2935003bb3f7376e124521-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1458/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - apixaban</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1458/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp656032a84c2935003bb3f7376e124521"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - apixaban"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Apixaban Accord is and what it is used for</li><li>What you need to know before you take Apixaban Accord</li><li>How to take Apixaban Accord</li><li>Possible side effects</li><li>How to store Apixaban Accord</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What apixaban is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What apixaban is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Apixaban Accordcontains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.</p><p>Apixaban Accord is used in adults:</p><ul><li><p>to prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations. After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. This can cause the legs to swell, with or without pain. If a blood clot travels from your leg to your lungs, it can block blood flow causing breathlessness, with or without chest pain. This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.</p></li><li><p>to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or travelto other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.</p></li><li><p>to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p></li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take apixaban"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take apixaban"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Apixaban Accordif:</p><ul><li>you are allergic to apixaban or any of the other ingredients of this medicine (listed in section 6)</li><li>you are bleeding excessively</li><li>you have a disease in an organ of the body that increases the risk of serious bleeding (such as an active or a recent ulcer of your stomach or bowel, recent bleeding in your brain)</li><li>you have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)</li><li>you are taking medicines to prevent blood clotting (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open, or if a tube is inserted into your blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).</li></ul><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:</p><ul><li>an increased risk of bleeding, such as:</li></ul><p>bleeding disorders, including conditions resulting in reduced platelet activity</p><p>very high blood pressure, not controlled by medical treatment</p><p>you are older than 75 years</p><p>you weigh 60 kg or less</p><ul><li>a severe kidney disease or if you are on dialysis</li><li>a liver problem or a history of liver problems<br/>This medicine will be used with caution in patients with signs of altered liver function.</li><li>had a tube (catheter) or an injection into your spinal column (for anaesthesia or pain reduction), your doctor will tell you to take this medicine 5 hours or more after catheter removal</li><li>if you have a prosthetic heart valve</li><li>if your doctor determines that your blood pressure is unstable</li><li>if another treatment or surgicalprocedure to remove ablood clot from your lungs is planned</li></ul><p>Take special care with Apixaban Accord</p><ul><li>if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots),.In that casetell your doctor who will decide if the treatment may need to be changed.</li></ul><p>If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding ask your doctor.</p><p>Children and adolescents</p><p>This medicine is not recommended in children and adolescents under 18 years of age.</p><p>Other medicines and Apixaban Accord</p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may increase the effects of Apixaban Accord and some may decrease its effects. Your doctor will decide, if you should be treated with Apixaban Accord when taking these medicines and how closely you should be monitored.</p><p>The following medicines may increase the effects of Apixaban Accordand increase the chance for unwanted bleeding:</p><ul><li>some medicines for fungal infections (e.g., ketoconazole,.)</li><li>some antiviral medicines for HIV / AIDS (e.g., ritonavir)</li><li>other medicines that are used to reduce blood clotting (e.g., enoxaparin,)</li><li>anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding.</li><li>medicines for high blood pressure or heart problems (e.g., diltiazem)</li><li>antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin norepinephrine re-uptake inhibitors</li></ul><p>The following medicines may reduce the ability of Apixaban Accord to help prevent blood clots from forming:</p><ul><li>medicines to prevent epilepsy or seizures (e.g., phenytoin,)</li><li>St John s Wort (a herbal supplement used for depression)</li><li>medicines to treat tuberculosis or other infections (e.g., rifampicin)</li></ul><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>The effects of Apixaban Accord on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant. Contact your doctor immediately if you become pregnant while taking this medicine.</p><p>It is not known if Apixaban Accord passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you whether to stop breast-feeding or to stop/not start taking this medicine.</p><p>Driving and using machines</p><p>Apixaban Accord has not been shown to impair your ability to drive or use machine.</p><p>Apixaban Accordcontains lactose (a type of sugar) and sodium</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.<br/>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodium- free".</p></div>
</text>
</section>
<section>
<title value="3. How to take apixaban"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take apixaban"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>Dose</p><p>Swallow the tablet with a drink of water. Apixaban Accordcan be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to takeApixaban Accord. The tablet may be crushed and mixed with water, or 5% glucose in water, or apple juice or apple puree, immediately before you take it.</p><p>Instructions for crushing:</p><ul><li>Crush the tablets with a pestle and mortaror with the convex side of a spoon on a plate.</li><li>Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.</li><li>Swallow the mixture.</li><li>Rinse the pestle andmortar or the spoon and plate)you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse. If necessary, your doctor may also give you the crushed Apixaban Accordtablet mixed in 60 mL of water or 5% glucose in water, through a nasogastric tube.</li></ul><p>Take Apixaban Accord as recommended for the following:</p><p>To prevent blood clots from forming after hip or knee replacement operations. The recommended dose is one tablet of Apixaban Accord 2.5 mg twice a day. For example, one in the morning and one in the evening.<br/>You should take the first tablet 12 to 24 hours after your operation.</p><p>If you have had a major hip operation you will usually take the tablets for 32 to38 days If you have had a major knee operation you will usually take the tablets for 10 to 14 days</p><p>To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.</p><p>The recommended dose is one tablet of Apixaban Accord 5 mg twice a day.</p><p>The recommended dose is one tablet of Apixaban Accord2.5 mg twice a day if:</p><ul><li><p>you have severely reduced kidney function</p></li><li><p>two or more of the following apply to you:</p></li><li><p>your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater)</p></li><li><p>you are 80 years old or older</p></li><li><p>your weight is 60 kg or lower.</p></li></ul><p>The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.</p><p>To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs</p><p>The recommended dose is two tablets of Apixaban Accord 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening. After 7 days the recommended dose is one tablet of Apixaban Accord 5 mg twice a day, for example, one in the morning and one in the evening.</p><p>For preventing blood clots from re-occurring following completion of 6 months of treatment</p><p>The recommended dose is one tablet of Apixaban Accord 2.5 mg twice a day for example, one in the morning and one in the evening.<br/>Your doctor will decide how long you must continue treatment for.</p><p>Your doctor might change your anticoagulant treatment as follows:</p><ul><li><p>Changing from Apixaban Accord to anticoagulant medicines Stop taking Apixaban Accord. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.</p></li><li><p>Changing from anticoagulant medicines to Apixaban Accord Stop taking the anticoagulant medicines. Start treatment with Apixaban Accord at the time you would have had the next dose of anticoagulant medicine, then continue as normal.</p></li><li><p>Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin) to Apixaban AccordStop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking Apixaban Accord .</p></li><li><p>Changing from Apixaban Accordto anticoagulant treatment containing vitamin K antagonist (e.g., warfarin). If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Apixaban Accordfor at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking Apixaban Accord .</p></li></ul><p>Patients undergoing cardioversion</p><p>If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take this medicine at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.</p><p>If you take more Apixaban Accord than you should</p><p>Tell your doctor immediately if you have taken more than the prescribed dose of this medicine. Take the medicine pack with you, even if there are no tablets left.</p><p>If you take more Apixaban Accord than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery, blood transfusions or other treatments that may reverse anti-factor Xa activity may be required.</p><p>If you forget to take Apixaban Accord</p><ul><li><p>Take the dose as soon as you remember and:</p></li><li><p>take the next dose of Apixaban Accordat the usual time</p></li><li><p>then continue as normal.</p></li></ul><p>If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.</p><p>If you stop taking Apixaban Accord</p><p>Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Apixaban Accord can be given for three different medical conditions. The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below.For these conditions, the most common general side effect of this medicine is bleeding which may be potentially life threatening and require immediate medical attention.</p><p>The following side effects are known if you take Apixaban Accord to prevent blood clots from forming after hip or knee replacement operations.</p><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li><p>Anaemia which may cause tiredness or paleness</p></li><li><p>Bleeding including:</p></li><li><p>bruising and swelling</p></li><li><p>Nausea (feeling sick) Uncommon side effects (may affect up to 1 in 100 people)</p></li><li><p>Reduced number of platelets in your blood (which can affect clotting)</p></li><li><p>Bleeding:</p></li><li><p>occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site</p></li><li><p>in your stomach, bowel or bright/red blood in the stools</p></li><li><p>blood in the urine</p></li><li><p>from your nose</p></li><li><p>from the vagina</p></li><li><p>Low blood pressure which may make you feel faint or have a quickened heartbeat</p></li><li><p>Blood tests may show:</p></li><li><p>abnormal liver function</p></li><li><p>an increase in some liver enzymes</p></li><li><p>an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.</p></li><li><p>Itching</p></li></ul><p>Rare side effects (may affect up to 1 in 1,000 people)</p><ul><li><p>Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.</p></li><li><p>Bleeding:</p></li><li><p>into a muscle</p></li><li><p>in your eyes</p></li><li><p>from your gums and blood in your spit when coughing</p></li><li><p>from your rectum</p></li><li><p>Hair loss</p></li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li><p>Bleeding:</p></li><li><p>in your brain or in your spinal column,</p></li><li><p>in your lungs or your throat</p></li><li><p>in your mouth</p></li><li><p>into your abdomen or space behind your abdominal cavity</p></li><li><p>from a haemorrhoid</p></li><li><p>tests showing blood in the stools or in the urine</p></li><li><p>Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme).</p></li><li><p>Blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising</p></li></ul><p>The following side effects are known if you take Apixaban Accord to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.</p><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li><p>Bleeding including:</p></li><li><p>in your eyes</p></li><li><p>in your stomach or bowel</p></li><li><p>from your rectum</p></li><li><p>blood in the urine</p></li><li><p>from your nose</p></li><li><p>from your gums</p></li><li><p>bruising and swelling</p></li><li><p>Anaemia which may cause tiredness or paleness</p></li><li><p>Low blood pressure which may make you feel faint or have a quickened heartbeat</p></li><li><p>Nausea (feeling sick)</p></li><li><p>Blood tests may show:</p></li><li><p>an increase in gamma-glutamyltransferase (GGT)</p></li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li><p>Bleeding:</p></li><li><p>in your brain or in your spinal column</p></li><li><p>in your mouth or blood in your spit when coughing</p></li><li><p>into your abdomen, or from the vagina</p></li><li><p>bright/red blood in the stools</p></li><li><p>bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site</p></li><li><p>from a haemorrhoid</p></li><li><p>tests showing blood in the stools or in the urine</p></li><li><p>Reduced number of platelets in your blood (which can affect clotting)</p></li><li><p>Blood tests may show:</p></li><li><p>abnormal liver function</p></li><li><p>an increase in some liver enzymes</p></li><li><p>an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes</p></li><li><p>Skin rash</p></li><li><p>Itching</p></li><li><p>Hair loss</p></li><li><p>Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.</p></li></ul><p>Rare side effects (may affect up to 1 in 1,000 people)</p><ul><li><p>Bleeding:</p></li><li><p>in your lungs or your throat</p></li><li><p>into the space behind your abdominal cavity</p></li><li><p>into a muscle</p></li></ul><h2 id="very-rare-side-effects-may-affect-up-to-1-in-10000-people">Very rare side effects (may affect up to 1 in 10,000 people)</h2><p>Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme).</p><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>Blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising.</li></ul><p>The following side effects are known if you take Apixaban Accord to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.</p><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li><p>Bleeding including:</p></li><li><p>from your nose</p></li><li><p>from your gums</p></li><li><p>blood in the urine</p></li><li><p>bruising and swelling</p></li><li><p>in your stomach, your bowel, from your rectum</p></li><li><p>in your mouth</p></li><li><p>from the vagina</p></li><li><p>Anaemia which may cause tiredness or paleness</p></li><li><p>Reduced number of platelets in your blood (which can affect clotting)</p></li><li><p>Nausea (feeling sick)</p></li><li><p>Skin rash</p></li><li><p>Blood tests may show:</p></li><li><p>an increase in gamma-glutamyltransferase (GGT) or alanine aminotransferase (ALT)</p></li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li><p>Low blood pressure which may make you feel faint or have a quickened heartbeat</p></li><li><p>Bleeding:</p></li><li><p>in your eyes</p></li><li><p>in your mouth or blood in your spit when coughing</p></li><li><p>bright/red blood in the stools</p></li><li><p>tests showing blood in the stools or in the urine</p></li><li><p>bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site</p></li><li><p>from a haemorrhoid</p></li><li><p>into a muscle</p></li><li><p>Itching</p></li><li><p>Hair loss</p></li><li><p>Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.</p></li><li><p>Blood tests may show:</p></li><li><p>abnormal liver function</p></li><li><p>an increase in some liver enzymes</p></li><li><p>an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.</p></li></ul><p>Rare side effects (may affect up to 1 in 1,000 people)</p><p>Bleeding:</p><ul><li>in your brain or in your spinal column</li><li>in your lungs</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><p>Bleeding:</p><ul><li>into your abdomen or the space behind your abdominal cavity</li><li>Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme).</li><li>Blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising.</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store apixaban"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store apixaban"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Apixaban Accord contains</p><ul><li>The active substance is apixaban. Each tablet contains 2.5 mg of apixaban.</li><li>The other ingredients are:</li></ul><ul><li>Tablet core: Lactose (see section 2), cellulose microcrystalline, croscarmellose sodium, sodium laurilsulfate, magnesium stearate</li><li>Film coat: Lactose monohydrate (see section 2), hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172)</li></ul><p>What Apixaban Accord looks like and contents of the pack</p><p>The film-coated tablets are yellow, round shaped, biconvex, film coated tablet debossed with IU1 on one side and plain on the other side.</p><p>PVC/PVdC-Aluminium blisters are available in 10, 14, 20, 28, 56, 60, 100, 112, 168, and 200 film-coated tablets.</p><p>PVC/PVdC-Aluminium blisters are available in perforated unit dose blisters of 10 x 1, 20 x 1, 28 x 1, 56 x 1, 60 x 1, 100 x 1 and 168 x 1 film-coated tablet.</p><p>HDPE bottle with polypropylene child resistant/continues threaded closure containing 60, 100, 168, 180, 200 and 1,000 film-coated tablets.</p><p>Not all pack sizes may be marketed.</p><p>Patient Alert Card: handling information</p><p>Inside the Apixaban Accordpack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card.</p><p>This Patient Alert Card includes information that will be helpful to you and alert other doctors that you are taking Apixaban Accord. You should keep this card with you at all times.</p><ol type="1"><li>Take the card</li><li>Separate your language as needed (this is facilitated by the perforated edges)</li><li>Complete the following sections or ask your doctor to do it:</li></ol><ul><li><p>Name:</p></li><li><p>Birth Date:</p></li><li><p>Indication:</p></li><li><p>Dose : ........mg twice daily</p></li><li><p>Doctor's Name:</p></li><li><p>Doctor's telephone:</p></li></ul><ol start="4" type="1"><li>Fold the card and keep it with you at all times Marketing Authorisation Holder and Manufacturer</li></ol><p>Marketing Authorisation Holder</p><p>Accord Healthcare S.L.U. World Trade Center, Moll de Barcelona, s/n, Edifici Est, 6a Planta, 08039 Barcelona, Spain</p><p>Manufacturer LABORATORI FUNDACI DAU C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona, 08040 Barcelona, Spain</p><p>Accord Healthcare Polska Sp. z.o.o. ul.Lutomierska 50, 95-200, Pabianice, Poland</p><p>Pharmadox Healthcare Limited KW20A Kordin Industrial Park, Paola PLA 3000, Malta</p><p>This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p><p>Package leaflet: Information for the user</p><p>Apixaban Accord 5 mg film-coated tablets apixaban</p><p>Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.</p><ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor, pharmacist or nurse.</li><li>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</li><li>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.</li></ul></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp656032a84c2935003bb3f7376e124521"/>
<resource>
<MedicinalProductDefinition>
<id value="mp656032a84c2935003bb3f7376e124521"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp656032a84c2935003bb3f7376e124521"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp656032a84c2935003bb3f7376e124521</b></p><a name="mp656032a84c2935003bb3f7376e124521"> </a><a name="hcmp656032a84c2935003bb3f7376e124521"> </a><a name="mp656032a84c2935003bb3f7376e124521-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1458/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Apixaban Accord 2.5 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1458/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Apixaban Accord 2.5 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
